contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


redeye-faron-pharmaceuticals-h2-en-route-to-pivotal-studies

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

For me, the biggest uncertainty regarding Bex is the highly unpredictably varying research results. At ASH, an attempt was made to highlight the high CR responses in TP53 mutants in the first-line, which can be explained at least in part by patients who received a transplant. overshadowed by these results in the presentation were the rather ordinary results for non-mutant patients in the first-line. For r/r patients, development has also been quite modest over the last year. At ASH 2024, results for 20 patients were presented:  After that, 12 more patients were enrolled in the study, and their responses can be calculated from Esmo’s slides:  The ORR for the first 20 patients was 80%, and for the next 12 patients, the ORR was 33%. The CR + mCR + PR responses for the first 20 patients were 70%, for the next 12 patients a maximum of 25%. NOTE! at least one patient who achieved a PR response has improved from the 2024 situation. Of the first 20 patients, 20% received no response, for the next 12 patients, the figure was 67%. This (either) is not a catastrophe in my opinion, but with these patient numbers, there is a huge amount of variation in the results. Monitoring things is not made any easier by Faron’s very sparse communication, and partly because of this, the air is filled with all kinds of speculation and interpretation of Juho’s eyebrow position.

It would probably be better if the scientific aspect were not reported at all, and publications were only referred to laconically. Because complex scientific matters simply cannot be explained. As a layman, I don’t even think about these things that closely, as they are not essential from an investment case perspective; they are just background niche science.

How many presumed PhDs and how much time were needed to understand a single stock exchange release. If the stock exchange release were consumer marketing, this would reek of misleading information (which is at least reprehensible). There are probably also separate rules related to the marketing of investment products (perhaps also applies to stocks). Someone else can figure that out. The burden of proof / burden of explanation will now shift to Faron. Props to Clark for persistence and to Pat for the investigative (and innovative) detective work. It was not a pleasant day for a layman to follow this episode from the sidelines.

Well yes, this is just because I don’t understand the text I’m reading. Luckily, you wise ones are blessed with the gifts of understanding.

I also looked at this, and yes, TI generally refers to red blood cell TI. Here, platelet TI has also been included in the total percentage, without it being specifically mentioned. That is also misleading, although I don’t consider it as serious an error as that baseline TD-TI conversion.

It feels like everything here revolves around one person. One must remember that the first payday is partnering, even though it will still take about a couple of years until the sales permit!

BioSpace – 8 Dec 25              Faron Presents Updated BEXMAB Data at ASH 2025: Deep and Durable Responses in...                              Beksmarilimabi** supports bone marrow recovery** In a study of previously untreated HR-MDS, 57% of baseline transfusion-dependent (TD) patients achieved transfusion independence (TI). In the entire HR-MDS BEXMAB study population, 23% of transfusion-dependent patients achieved independence. The durability of TI was robust, with 65% of patients participating in the study remaining transfusion-independent throughout the treatment. Analysis of bone marrow samples confirmed that the treatment increases the number of red blood cell, platelet, and leukocyte stem cells, providing biological validation for the clinical improvement in blood counts. Faron’s Chief Medical Officer, Dr. Petri Bono, added: “The new data on transfusion independence are clinically highly significant. For MDS patients, freedom from regular transfusions is a significant determinant of quality of life. By demonstrating that we can make more than half of frontline transfusion-dependent patients independent and at the same time promote deep molecular remissions in high-risk genetic subgroups, we confirm that beksmarilimabi acts on cancer cells and actively rehabilitates the bone marrow environment, which is a key differentiator compared to classic toxic drugs whose sole purpose is to kill cancer cells.” The combination continues to have an excellent safety profile. In the HR-MDS cohort, no Grade 5 adverse events related to beksmarilimabi use were observed. The encouraging safety profile and clear efficacy signals support the progression of beksmarilimabi to a randomized Phase 3 registration study, addressing the urgent unmet medical need for HR-MDS patients. I don’t know what the correct reporting method is, but I’m still not putting notes on the side.

Faron Pharmaceuticals

Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H2 report. The company managed to reduce its OPEX as it continues its measures for improved cost efficiency...

<div class="mfn-body"><p>Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H2 report. The company managed to reduce its OPEX as it continues its measures for improved cost efficiency. However, the report did not include any major surprises as free cash flow was in line with our expectation. With upcoming BEXMAB read-outs, a planned pivotal study and a potential license deal on the horizon, we see exciting times ahead for the company.</p><p><a rel="noopener" href="https://www.redeye.se/research/1084344/faron-pharmaceuticals-h2-en-route-to-pivotal-studies?utm_source=MFN&amp;utm_medium=pmcour">Read more and download the Research Update.</a><br>&nbsp;<br>Follow companies at Redeye to receive the latest equity research within Life Science and Technology.<br>&nbsp;<br>This is a press release from Redeye - Research Powered Investment Banking. <a rel="noopener" href="https://www.redeye.se/">www.redeye.se/</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/dafe63f0-3f4b-4792-b976-55188033615f/faron-pharmaceuticals-h2-en-route-to-pivotal-studies.pdf" class="mfn-generated mfn-primary">Faron Pharmaceuticals H2 - En route to pivotal studies</a></p></div>